MARKET

CTXR

CTXR

Citius Pharmaceuticals Inc
NASDAQ
0.4928
-0.0335
-6.37%
After Hours: 0.4928 0 0.00% 16:15 11/10 EST
OPEN
0.5290
PREV CLOSE
0.5263
HIGH
0.5447
LOW
0.4759
VOLUME
302.13K
TURNOVER
--
52 WEEK HIGH
1.540
52 WEEK LOW
0.3699
MARKET CAP
13.53M
P/E (TTM)
-0.2311
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CTXR last week (1102-1106)?
Weekly Report · 1d ago
Citius Pharmaceuticals Reports LYMPHIR Quality-of-Life Improvements in Study 302
TipRanks · 6d ago
Weekly Report: what happened at CTXR last week (1026-1030)?
Weekly Report · 11/02 09:43
Citius Oncology Reports Preliminary Q4 FY2026 LYMPHIR Wholesaler Unit Sales More Than Doubling 120% To 792 Units, With 950 Institutional Vial Orders And 54 Institutions Ordering The CTCL Treatment
Benzinga · 10/26 17:51
Citius reports 120% growth in shipments of LYMPHIR units to U.S. wholesalers
TipRanks · 10/26 17:05
Weekly Report: what happened at CTXR last week (1019-1023)?
Weekly Report · 10/26 09:43
Weekly Report: what happened at CTXR last week (1012-1016)?
Weekly Report · 10/19 09:43
Weekly Report: what happened at CTXR last week (1005-1009)?
Weekly Report · 10/12 09:45
More
About CTXR
Citius Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of first-in-class critical care products, with a pipeline of anti-infectives in oncology, adjunct cancer care, stem cell therapy and prescription products. The Company's FDA approved LYMPHIR candidate is a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Its late-stage pipeline also includes Mino-Lok, and CITI-002 (Halo-Lido). Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs) and central line associated bloodstream infections (CLABSIs). Halo-Lido is a topical formulation of halobetasol propionate, a corticosteroid, and lidocaine that is intended for the treatment of hemorrhoids. The Company is also seeking to develop and commercialize the NoveCite mesenchymal stem cells (NC-iMSCs) to treat acute respiratory conditions with a near term focus on ARDS.

Webull offers Citius Pharmaceuticals Inc stock information, including NASDAQ: CTXR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CTXR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CTXR stock methods without spending real money on the virtual paper trading platform.